Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that, following its approval in 2009, Schering- Plough/Novartis's formoterol/mometasone will become the clinical gold standard for asthma by 2011, owing to its competitive advantages in delivery over AstraZeneca's Symbicort.

According to the new report entitled Asthma: Novel Product Differentiation Remains a Key Challenge, formoterol/mometasone may have a greater number of inhaler device options if Schering-Plough/Novartis decides to pursue both metered dose inhaler (MDI) and dry powder inhaler (DPI) formulations of the drug. Surveyed primary care physicians indicated they would prescribe formoterol/mometasone to 34% of their patients with persistent asthma.

"Pulmonologists emphasize that delivery device and formulation can influence patient compliance and, in turn, outcomes -- as a result, they value a variety of options for their patients," said Cindy Mundy, Ph.D., director at Decision Resources. "Although Schering-Plough/Novartis has yet to announce the delivery device in which the drug will be administered, formoterol/mometasone could be made available as both an MDI and a DPI, which is the same for the current asthma market leader -- GlaxoSmithKline's Advair/Seretide/Adoair."

About Asthma: Novel Product Differentiation Remains a Key Challenge

Asthma: Novel Product Differentiation Remains a Key Challenge, is a DecisionBase 2008 report from Decision Resources. DecisionBase 2008 combines market forecasts with clinical and commercial endpoints to assess market share projections in 35 indications. These outputs are driven by quantitative and qualitative primary research. DecisionBase 2008 provides detailed market share, patient share, and price-per-day projections for emerging drugs in development. The market share projections are based on prescriber surveys that compare physicians' expectations of a potential target product profile with an emerging product profile of the leading drugs in development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources, Inc. ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:   Elizabeth Marshall   Decision Resources, Inc.   781-296-2563 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,

Struggling Medical Delivery System Impacts Hospitals and Physicians Hardest

View Now